Search the NeLM

Medicines A-Z
Find key information about medicines by name (prototype)
NeLM news service
European CHMP issues positive opinion on marketing authorisation application for Docefrez® (generic docetaxel)

Source: EMEA

Date published: 19/02/2010 17:44

Summary
by: Yuet Wan

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion, recommending the granting of a marketing authorisation for Docefrez (generic docetaxel), for the treatment of breast cancer, NSCLC, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

Press release
Link to Opinion

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.
Related evidence
8.1.5 Other antineoplastic drugs
09/02/2012
London Cancer New Drugs Group Rapid Review: Cabazitaxel for the second-line treatment of hormone-refractory metastatic prostate cancer
09/02/2012
London Cancer New Drugs Group Rapid Review: Everolimus for advanced pancreatic neuroendocrine tumours (pNET)
09/02/2012
London Cancer New Drugs Group Rapid Review: Erlotinib for the third or fourth-line treatment of NSCLC
Cancer: breast
07/02/2012
London Cancer New Drugs Group Rapid Review: Lapatinib with capecitabine following disease progression on trastuzumab for metastatic breast cancer
15/12/2011
Systematic review and economic analysis: Lapatinib and trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone receptor
14/12/2011
NICE issues guidance on fulvestrant for the treatment of locally advanced or metastatic breast cancer
Cancer: gastroenterological
07/02/2012
London Cancer New Drugs Group Rapid Review: SIRT WITH YTTRIUM-90 MICROSPHERES FOR THE THIRD LINE TREATMENT OF LIVER METASTASES FROM COLORECTAL CANCER
25/01/2012
NICE issues final guidance on cetuximab, bevacizumab and panitumumab for metastatic colorectal cancer (second-line)
15/12/2011
SIGN updates guideline on diagnosis and management of colorectal cancer
Cancer: lung
09/02/2012
London Cancer New Drugs Group Rapid Review: Erlotinib for the third or fourth-line treatment of NSCLC
08/02/2012
London Cancer New Drugs Group Rapid Review:Erlotinib for the first-line treatment of advanced NSCLC with EGFR mutation
17/01/2012
SMC accepts erlotinib (Tarceva®) for first-line treatment of patients with advanced NSCLC with EGFR-activating mutations
Cancer: other
09/02/2012
London Cancer New Drugs Group Rapid Review: Everolimus for advanced pancreatic neuroendocrine tumours (pNET)
31/12/2011
Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma
26/10/2011
NICE issues guidance on mifamurtide for the treatment of osteosarcoma – TA 235
Cancer: prostate
09/02/2012
London Cancer New Drugs Group Rapid Review: Cabazitaxel for the second-line treatment of hormone-refractory metastatic prostate cancer
08/11/2011
SMC does not recommend cabazitaxel (Jevtana®) for the treatment of prostate cancer
05/10/2011
Degarelix for advanced hormone dependent prostate cancer
Related news
8.1.5 Other antineoplastic drugs
08/02/2012
Horizon scanning: FDA Grants priority review of pertuzumab for untreated HER2-Positive metastatic breast cancer
07/02/2012
Meta-analysis finds VEGFR tyrosine kinase inhibitors are associated with increased risk of fatal adverse events
02/02/2012
Positive phase III data on prostate cancer drug MDV3100 to be presented at conference
Cancer: breast
08/02/2012
Horizon scanning: FDA Grants priority review of pertuzumab for untreated HER2-Positive metastatic breast cancer
07/02/2012
Subanalysis of the MAP.3 study finds exemestane for primary prevention of breast cancer worsens age-related BMD decreases
07/02/2012
NICE issues preliminary guidance (ACD) on four tests to guide selection of chemotherapy regimes in breast cancer management
Cancer: gastroenterological
02/02/2012
Positive phase II data on masitinib in imatinib-resistant GIST
02/02/2012
Equity and Excellence for bowel cancer
01/02/2012
FDA grants imatinib (Gleevec®) regular approval for use following GIST surgical removal
Cancer: lung
06/02/2012
Addition of thalidomide to paclitaxel and carboplatin shows no benefit in patients with NSCLC
26/01/2012
RCT: Erlotinib vs. standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC)
24/01/2012
Results of TITAN study comparing erlotinib to chemotherapy (docetaxel or pemetrexed) in the second-line treatment of advanced NSCLC
Cancer: other
23/01/2012
Phase III study finds acceleration of radiotherapy of no benefit in the treatment of locally advanced head and neck carcinoma
10/01/2012
Review: Multiple myeloma
09/12/2011
Concurrent chemoradiotherapy plus adjuvant chemotherapy vs concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma: RCT
Cancer: prostate
09/02/2012
FDA to discuss license extension application for denosumab (Xgeva) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases
08/02/2012
Editorial - Cardiovascular risk in androgen suppression
02/02/2012
NICE issues Appraisal Consultation Document on abiraterone for metastatic, castration resistant prostate cancer
Back